TickerTalks
Browse all tickers →
TickerTalks›$NBTX
NBNBTX

Nanobiotix S.A.

$NBTX·$1.9B·Biotechnology·Healthcare
$43.70-3.2%YTD+74.0%1Y+402.3%
Mentions · last 7 days
2026-08-18: 0 posts2026-08-19: 5 posts2026-08-20: 3 posts2026-08-21: 1 posts2026-08-22: 0 posts160%
Price updated 7m ago·X counts updated 6d ago
NBNBTX
$NBTXNanobiotix S.A.
$43.70-3.23%16 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $NBTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-08-21

The move is getting stronger, with heavier trading behind it.

Radiotherapy-platform biotech up 5x in a year on NBTXR3 optionality — the physics story is running, the revenue isn't yet.

Nanobiotix is a French clinical-stage biotech developing NBTXR3 — a nanoparticle radioenhancer that, when injected into a tumor and combined with radiotherapy, increases local energy deposition. The physics-plus-biology hybrid mechanism is the specific differentiator, and there's a partnership with Janssen (J&J) providing validation.

  • Q2 (last-available detailed period, 2025-06) revenue was $27M growing off a very low base, then Q4 stepped down to $3M — the numbers are collaboration-milestone-driven and highly episodic; not a real business run-rate yet.
  • Stock is +74% year-to-date and +412% over 12 months, sitting at the 73rd percentile of its 52-week range and 41% above the 200-day trend — a genuinely huge move driven by the radiotherapy-platform thesis, and the tape is telling you the market is now seriously modelling NBTXR3 as a commercial asset.
  • Trades at $1.9B market cap on essentially zero recurring revenue — every dollar of value is optionality on the pipeline; the 2026 revenue estimate of $34.7M steps up modestly to $42.8M in 2027, so the analyst model doesn't need explosive commercial-revenue to justify the current price.
  • Coverage flags note the equity has an unusual balance-sheet setup — the seekingalpha 'royalty-backed physics platform hidden inside a biotech' framing captures why traditional biotech-multiple math doesn't quite fit.

What sustains the accelerating call is Sep 29 Q2 European (semi-annual) print confirming Janssen partnership progression alongside a specific NBTXR3 Phase 3 timeline update. What invalidates it is a Janssen-side de-prioritization or a Phase 3 safety signal; the equity is a highly leveraged bet on one asset extending, so any specific negative catalyst hits hard.

What to watch: Sep 29 Q2 (European semi-annual) earnings and business update — NBTXR3 clinical progress and Janssen partnership detail are the two data points. Watch for any specific Phase 3 protocol/design disclosure.

On the calendar: 2026-09-29 — Q2 earnings/H1 report

Read the AI verdict + X sentiment for $NBTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing NBTXR3, hafnium oxide nanoparticles injected into tumors to amplify radiotherapy across multiple cancer types.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NBTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NBTX

Neutral — Clinical-stage biotech developing NBTXR3, hafnium oxide nanoparticles injected into tumors to amplify radiotherapy across multiple cancer types; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+55.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-67.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-74.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-36.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
58.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
31.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
100%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q4 2025Mar 31, 2026$-0.46$0.30-250.7%
Q2 2025Sep 30, 2025$-0.13$-0.25+45.9%
Q1 2025Apr 2, 2025$-1.01$-0.62-63.5%
Q3 2024Nov 12, 2024$-0.50$-0.51+2.5%
Next earningsTue, Sep 29·consensus EPS $-0.13

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$3.0M-90.9%100%-387%$-0.39$-16.4M
Q2 FY25$26.6M+708.9%100%3.0%$-0.11$-17.6M
Q4 FY24$-16.5M-578.1%100%271%$-0.98$-14.1M
Q2 FY24$9.3M+598.9%100%-255%$-0.46$-6.3M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$34.7M$26.7M – $46.9M-$0.21-$0.90 – $0.483
FY27$42.8M$33.0M – $57.8M-$0.26-$2.00 – $1.503
FY28$108.3M$83.4M – $146.3M$0.68$0.48 – $0.991
FY29$100.1M$77.1M – $135.2M$0.49$0.34 – $0.712
FY30$140.3M$108.1M – $189.6M$0.66$0.47 – $0.971

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.76%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+15.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+42.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 41.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)May 22424B5
AI summary

Nanobiotix S.A. (NBTX) priced a global equity offering of approximately €85 million on May 22, 2026, comprising 2,184,662 ordinary shares plus 345,099 pre-funded warrants, with the U.S. portion delivered as ADSs (225,373 shares) and the European portion (1,959,289 shares plus warrants) addressed to qualified investors only. This is a primary offering representing new dilution for existing shareholders. As a clinical-stage radiotherapy enhancement company, proceeds are expected to fund ongoing oncology programs; the concurrent pricing of both ADS and ordinary share tranches is consistent with Nanobiotix's dual-listed structure.

424B5Prospectus supplement (offering)May 20424B5
AI summary

Nanobiotix S.A. (NBTX) filed a preliminary 424B5 prospectus supplement on May 20, 2026 for a global equity offering of approximately €75 million of ordinary shares and pre-funded warrants, with exact share counts and warrant amounts blank pending final pricing. Filed one day before the final 424B5, this preliminary filing establishes the offering structure — a dual U.S./European offering with ADSs for U.S. investors and ordinary shares for European qualified investors. The preliminary status means specific per-share pricing and final allocation are not yet disclosed.

+ 26 other (22 6-Ks · 2 13Gs · 1 S-8 · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Voting Rights and Shares Capital of the Companyglobenewswire.com·3d agoVoting Rights and Shares Capital of the Companyglobenewswire.com·29d agoNanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platformseekingalpha.com·64d agoNanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotechseekingalpha.com·77d agoVoting Rights and Shares Capital of the Companyglobenewswire.com·84d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $NBTX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport